• 제목/요약/키워드: SARS-CoV-2 vaccines

검색결과 58건 처리시간 0.02초

UHPLC/TOFHRMS analysis and anti-inflammatory effect of leaf extracts from Zizyphus jujuba in LPS-stimulated RAW264.7 cells

  • Hyun Ji Eo;Sun-Young Lee;Gwang Hun Park
    • Journal of Plant Biotechnology
    • /
    • 제50권
    • /
    • pp.27-33
    • /
    • 2023
  • Zizyphus jujube is a plant in the buckthorn family (Rhamnaceae) that has been the subject of research into antibacterial, antifungal and anti-inflammatory properties of its fruit and seed. However, few studies have investigated its leaves. In this study, the anti-inflammatory activity of ZJL (an extract of Z. jujube leaf) was evaluated to verify its potential as an anti-inflammatory agent and SARS-CoV-2 medicine, using nitric oxide (NO) assay, RT-PCR, SDSPAGE, Western blotting, and UHPLC/TOFHRMS analysis. We found that ZJL suppresed pro-inflammatory mediators such as NO, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-induced RAW264.7 cells. ZJL acted by inhibiting NF-KB and MAPK signaling pathway activity. We also confirmed that ZJL contains a phenol compound and flavonoids with anti-inflammatory activity such as trehalose, maleate, epigallocatechin, hyperoside, catechin, 3-O-coumaroylquinic acid, rhoifolin, gossypin, kaempferol 3-neohesperidoside, rutin, myricitrin, guaiaverin, quercitrin, quercetin, ursolic acid, and pheophorbide a. These findings suggest that ZJL may have great potential for the development of anti-inflammatory drugs and vaccines via inhibition of NF-κB and MAPK signaling in LPS-induced RAW264.7 cells.

Preparedness of Siddha system of medicine in practitioner perspective during a pandemic outbreak with special reference to COVID-19

  • Rajalakshmi, S.;Samraj, K.;Sathiyarajeswaran, P.;Kanagavalli, K.
    • 셀메드
    • /
    • 제10권4호
    • /
    • pp.29.1-29.6
    • /
    • 2020
  • COVID-19 (Corona Virus Disease-2019) is an infectious respiratory disease caused by the most recently discovered coronavirus, SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona virus-2). This new viral disease was unknown before the outbreak began in Wuhan, China, in December 2019. As of November 16th 2020, it affects about 54.3 million populations, death troll increased to 1.32 million cases in worldwide. Whereas in India 8.85 cases are infected with COVID-19, of which 1, 30, 112 cases were died. Till now there has been no specific anti-virus drug or vaccines are available for the treatment of this disease, the supportive care and non-specific treatment to the symptoms of the patient are the only options in Biomedicine, the entire world turns its attention towards alternative medicine or Traditional medicine. Siddha medicine is one of the primordial systems of medicine practiced in the southern part of India, it dealt a lot about pandemic, and its management. This review provides an insight into Pandemic in Siddha system and its management in both ancient history and modern history, National and state level Government policies related to current pandemic, World Health Organization (WHO) guidelines on usage of unproven drug during infectious disease outbreak, Preparedness of Siddha system during a pandemic outbreak Challenges and Recommendations.

The Effect on the Immune System in the Human Body Due to COVID-19: An Insight on Traditional to Modern Approach as a Preventive Measure

  • Sutradhar, Jugal;Sarkar, Bapi Ray
    • 대한약침학회지
    • /
    • 제24권4호
    • /
    • pp.165-172
    • /
    • 2021
  • The COVID-19, the most infectious pandemic disease arising due to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has caused huge issues globally. In this review, we discuss the impact of COVID-19 on the immune system of the human body and the protective mechanisms of the host immune system opposing viral infections. Here, we summarize the effect of the pandemic of the novel coronavirus disease on the immune system such as sleep and Behavioral Immune System (BIS) together with consideration of researcher's observation points of view. We draw particular attention to recent up-to-date reports concerning COVID-19 drugs as well as information about the landscape document for COVID-19 vaccines released by WHO (World Health Organization), and some adverse events of COVID-19 vaccination. Additionally, can take part in the preventive appraise in opposition within this pandemic severe COVID-19 infections disease may affect some outcome in physical exercise, physical movement, healthy diets, and good nutrition are significant for supporting the immune systems and summarize AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy) Indian medicinal systems guidelines for immunity boosting procedures during COVID-19 pandemic.

Confidence intervals for the COVID-19 neutralizing antibody retention rate in the Korean population

  • Apio, Catherine;Kamruzzaman, Md.;Park, Taesung
    • Genomics & Informatics
    • /
    • 제18권3호
    • /
    • pp.31.1-31.8
    • /
    • 2020
  • The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. No specific therapeutic agents or vaccines for COVID-19 are available, though several antiviral drugs, are under investigation as treatment agents for COVID-19. The use of convalescent plasma transfusion that contain neutralizing antibodies for COVID-19 has become the major focus. This requires mass screening of populations for these antibodies. While several countries started reporting population based antibody rate, its simple point estimate may be misinterpreted without proper estimation of standard error and confidence intervals. In this paper, we review the importance of antibody studies and present the 95% confidence intervals COVID-19 antibody rate for the Korean population using two recently performed antibody tests in Korea. Due to the sparsity of data, the estimation of confidence interval is a big challenge. Thus, we consider several confidence intervals using Asymptotic, Exact and Bayesian estimation methods. In this article, we found that the Wald method gives the narrowest interval among all Asymptotic methods whereas mid p-value gives the narrowest among all Exact methods and Jeffrey's method gives the narrowest from Bayesian method. The most conservative 95% confidence interval estimation shows that as of 00:00 on September 15, 2020, at least 32,602 people were infected but not confirmed in Korea.

Acute abdomen following COVID-19 vaccination: a systematic review

  • Nelson Luis Cahuapaza-Gutierrez;Renzo Pajuelo-Vasquez;Cristina Quiroz-Narvaez;Flavia Rioja-Torres;Maria Quispe-Andahua;Fernando M. Runzer-Colmenares
    • Clinical and Experimental Vaccine Research
    • /
    • 제13권1호
    • /
    • pp.42-53
    • /
    • 2024
  • Purpose: Conduct a systematic review of case reports and case series regarding the development of acute abdomen following coronavirus disease 2019 (COVID-19) vaccination, to describe the possible association and the clinical and demographic characteristics in detail. Materials and Methods: This study included case report studies and case series that focused on the development of acute abdomen following COVID-19 vaccination. Systematic review studies, literature, letters to the editor, brief comments, and so forth were excluded. PubMed, Scopus, EMBASE, and Web of Science databases were searched until June 15, 2023. The Joanna Briggs Institute tool was used to assess the risk of bias and the quality of the study. Descriptive data were presented as frequency, median, mean, and standard deviation. Results: Seventeen clinical case studies were identified, evaluating 17 patients with acute abdomen associated with COVID-19 vaccination, which included acute appendicitis (n=3), acute pancreatitis (n=9), diverticulitis (n=1), cholecystitis (n=2), and colitis (n=2). The COVID-19 vaccine most commonly linked to acute abdomen was Pfizer-BioNTech (messenger RNA), accounting for 64.71% of cases. Acute abdomen predominantly occurred after the first vaccine dose (52.94%). All patients responded objectively to medical (88.34%) and surgical (11.76%) treatment and were discharged within a few weeks. No cases of death were reported. Conclusion: Acute abdomen is a rare complication of great interest in the medical and surgical practice of COVID-19 vaccination. Our study is based on a small sample of patients; therefore, it is recommended to conduct future observational studies to fully elucidate the underlying mechanisms of this association.

해외 주요 국가의 5-11세 소아 코로나19 예방접종 정책 동향 (Latest Overseas Policy on Coronavirus Disease 2019 Vaccination for Children Aged 5 to 11)

  • 문지현;최영준;최윤영
    • Pediatric Infection and Vaccine
    • /
    • 제29권1호
    • /
    • pp.16-27
    • /
    • 2022
  • 우리 나라는 2022년 3월에 5-11세 소아의 코로나19 예방접종을 시작하였다. 5-11세 소아에서 중증 코로나19가 발생할 위험은 높지 않기 때문에, 이 연령에 대한 코로나19 예방접종 정책은 각 국가의 상황에 따라 상이하다. 본 논문에서는 해외 주요 국가의 5-11세 소아 코로나19 예방접종 관련 정책을 살펴보고, 5-11세 코로나19 예방접종을 시작하는 우리 나라에서 고려할 사항에 대하여 언급하였다.

Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort study

  • Naye Choi;Seung-Ah Choe;Yo Han Ahn;Young June Choe;Ju-Young Shin;Nam-Kyong Choi;Seong Heon Kim;Hee Gyung Kang
    • Childhood Kidney Diseases
    • /
    • 제27권1호
    • /
    • pp.34-39
    • /
    • 2023
  • Purpose: This article was to collect data on the safety of coronavirus disease 2019 (COVID-19) vaccines in children with underlying medical conditions. Methods: We constructed a prospective cohort of children and adolescents aged 5 to 19 years who had received at least one dose of COVID-19 vaccine. Patients diagnosed with and treated for chronic kidney disease, autoimmune disease, or other chronic conditions at the Seoul National University Children's Hospital were recruited from June to December 2022. A mobile survey questionnaire was sent to their guardians. The presence of adverse events on the day (day 0), 3 weeks (day 21), and 6 months (day 180) after the 1st dose of COVID-19 vaccine was recorded by the guardians. Results: A total of 73 children participated. The median age was 14 years, and 64.4% of the patients were male. On the day of immunization, 65.8% of the patients reported at least one adverse event. Pain at the injection site, fatigue, headache, arthralgia, and myalgia were the most common symptoms. The prevalence of adverse events decreased over time (65.8% on day 0, 27.4% between days 0 and 21, and 24.6% between days 21 and 180). Severe acute respiratory syndrome coronavirus 2 infection after the 1st dose occurred in 17 patients (23.3%) and one of the patients (5.88%) was hospitalized due to infection. Conclusions: Adverse events after COVID-19 vaccination were generally mild in children and adolescents with underlying medical conditions. Our findings provide evidence for the safety of COVID-19 vaccination in the vulnerable pediatric population.

COVID-19 단일 감염 환자와 COVID-19 및 인플루엔자 바이러스 동시 감염 환자의 혈액 검사 결과 및 증상 비교 (Comparison of Blood Test Results and Symptoms of Patients with COVID-19 Monoinfection and with COVID-19 and Influenza Virus Co-Infection)

  • 정보경;함승근;김재경
    • 대한임상검사과학회지
    • /
    • 제54권2호
    • /
    • pp.103-109
    • /
    • 2022
  • 2019년 12월 중국에서 바이러스성 폐렴을 일으키는 코로나 바이러스 질병 2019 (COVID-19)가 검출돼 전 세계로 빠르게 확산되어 수백만 명의 감염자와 사망자가 발생했다. 증상이 유사한 호흡기 바이러스 가운데 경기도의료원에 입원한 환자 35명이 2020년 11월부터 2021년 1월까지 인플루엔자 바이러스(인플루엔자바이러스 A·B)에 감염된 것으로 나타났다. 이들 환자의 기록과 건강검진을 위해 병원을 찾은 환자의 기록을 비교했다. 대상 환자 군에는 COVID-19 환자 30명, 인플루엔자 환자 5명, 비 감염 환자 121명이 포함됐다. 혈액학적 기록을 활용해 입원 당일 실시한 일반 혈액 검사와 생화학 검사 결과를 분석했다. COVID-19 및 인플루엔자에 동반 감염된 환자들은 단일 COVID-19 감염 그룹보다 젖산 탈수소효소(LDH), C-반응 단백질(CRP), 백혈구(WBC) 수치가 유의미하게 높았다. 적혈구 침전률과 COVID-19 감염 환자만 있는 림프구(Lymphocyte)가 다른 그룹에 비해 증가했다. 인플루엔자 감염군은 COVID-19와 인플루엔자에 동반 감염된 환자에 비해 발열의 빈도가 빈번했다. COVID-19에 감염된 단일 환자에 비해 공동 감염 그룹에서 유의미한 임상 특이 수치가 관찰되었다. 본 연구에서 나오는 결과로 COVID-19치료제와 백신개발에 이용하기를 기대한다.